Efeitos da boldenona e do estanazolol associados ou não à gonadotrofina coriônica humana no fígado e testículo de ratos

• Ano de defesa: 2018
• Autor(a) principal: Lhamas, Cibele Lima
• Orientador(a): Andrade, Cinthia Melazzo de
• Banca de defesa: Bueno, Andressa , Pinto Filho, Saulo Tadeu Lemos , Gutierres, Jessié Martins , Wolkmer, Patricia
• Tipo de documento: Tese
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de Santa Maria; Centro de Ciências Rurais
• Programa de Pós-Graduação: Programa de Pós-Graduação em Medicina Veterinária
• Departamento: Medicina Veterinária
• País: Brasil
• Palavras-chave em Português: Undecilenato de boldenona; Estanazolol; Fígado; Testículos; Estresse oxidativo; Marcador inflamatório; Gonadotrofina coriônica humana
• Palavras-chave em Inglês: Boldenone undecylenate; Stanazolol; Liver; Testicles; Oxidative stress; Inflammatory marker; Human chorionic gonadotrophin
• Área do conhecimento CNPq: CNPQ::CIENCIAS AGRARIAS::MEDICINA VETERINARIA
• Link de acesso: http://repositorio.ufsm.br/handle/1/15593

In the present thesis, under the format of two experiments, the deleterious effects of Boldenone Undecylenate (BOL) and Stanazolol (ST) in rats’ liver and testis were assessed. In the first experiment, the inflammatory, metabolic, and oxidative parameters were measured in rats’ liver when treated with either BOL or ST. In the second experiment, oxidative stress and inflammatory parameters were evaluated in rats’ testis treated with BOL associated or not to human chorionic gonadotrophin (hCG) in two dosages: 50U and 200U. In the first experiment, three protocols were established in order to verify which one would be the more deleterious for the users of this kind of anabolic steroids. Thereby, the protocol I represents the users who wish to accelerate the anabolic effects using higher dosages than those recommended, in a shorten time interval, the protocol II represents groups of users of anabolic steroids who choose a moderate dosage and intermediate time and protocol III represents users that reduce the dosage and prolong the exposure time aiming to reduce the androgenic effects. In the second experiment, eight protocols were made aiming to verify if the BOL exposure can be attenuated when using hCG in two dosages considered low, but in accordance to how they are administered, may have the reversion or prevention effect of the testicular damage. Therefore, the group I received only BOL vehicle; group II received BOL and hCH placebo in the cycle form; group III received BOL and three applications of hCG50 in the cycle form; group IV received BOL and three applications of hCG200 in the cycle form; group V received BOL and three applications of hCG50 in the reversion form; group VI received BOL and three applications of hCG200 in the reversion form; group VII received BOL and three applications of hCG placebo in the reversion form; group VIII received BOL and was kept with no applications of any substance until the whole spermatogenesis have finished (approximately 60 days). For the first experiment, our data indicate that the protocol I showed the most deleterious effects in the redox status, cellular infiltration markers, as well as for the metabolic functioning of the hepatic tissue. Concerning to the second experiment, our data indicate that hCG had beneficial effects either in 50U or 200U dosages considering the MPO marker, however the animals in the protocol VIII were better benefited in TBARS evaluation when compared to the animals that had the preventive treatment with hCG administered in cycle form. The present thesis demonstrates that decreasing the dose of anabolics may be less deleterious to the liver and that hCG is able to prevent inflammatory infiltrates in the testis when in use with anabolic steroids.